Helicobacter pylori: Primary susceptibility to clarithromycin in vitro in Nova Scotia

Canadian Journal of Gastroenterology

Volumn 11, Issue 4, 1997, Pages 298-300

  Best, Linda M ^a,b   Haldane, David J M ^a   Bezanson, Gregory S ^a   Veldhuyzen Van Zanten, Sander J O ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b Centre for Clinical Research   (Canada)

Author keywords

Clarithromycin; Helicobacter pylori

Indexed keywords

CLARITHROMYCIN; MACROLIDE;

ADOLESCENT; ADULT; AGAR GEL DIFFUSION; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; CANADA; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL;

EID: 0030993080     PISSN: 08357900     EISSN: None     Source Type: Journal    
DOI: 10.1155/1997/159637     Document Type: Article

References (20)

1. Blaser MJ, Perez-Perez GI, et al. Infection with Helicobacter pylori strains possessing cag A is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995;55:2111-5.
2. NIH Consensus Statement. Helicobacter pylori in peptic ulcer disease. JAMA 1994;272:65-9.
3. Veldhuyzen van Zanten SJO, Sherman PM. Helicobacter pylori infection as a cause of gastritis, duodenal ulcer, gastric cancer and nonulcer dyspepsia: a systematic overview. Can Med Assoc J 1994;150:177-85.
4. Graham DY, Lew CM, Malaty HM. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992;102:493-6.
5. Moayyedi P, Tompkins DS, Axon ATR. Determination of the optimum dose of omeprazole in a new triple therapy regimen for eradicating Helicobacter pylori. Gut 1994;35:S16.
6. AI Assi MT, Ramirez FC, Lew CM, Genta RM, Graham DY. Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection. Am J Gastroenterol 1994;89:203-5.
7. Lind T, Veldhuyzen van Zanten SJO, Unge P, et al. The MACH 1 study: optimal one-week treatment for H pylori defined? Gut 1995;37:A15.
8. Peterson WL, Graham DY, Marshall BJ, Blaser MJ, et al. Clarithromycin for eradication of Helicobacter pylori: a randomized double blind study. Am J Gastroenterol 1993;88;860-4.
9. Logan RPH, Gummett PA, Schaufelberger HD, et al. Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut 1994;35:323-6.
10. Lamouiliatte H, Cayla R, Forestier S, et al. Dual therapy versus triple therapy: high dose of lansoprazole plus amoxicillin in combination or not with clarithromycin for Helicobacter pylori infection. Out 1995;37(Suppl 1):A43.
11. Glupczynski Y, Goutier S, Van den Borre C, Butzler JP, Burette A. Surveillance of Helicobacter pylori resistance to antimicrobial agents in Belgium from 1989 to 1994. Gut 1995;37:A223.
12. Cayla R, Zerbib F, Talbi P, Mégraud F, Lamouliatte H. Pre and posttreatment clarithromycin resistance of Helicobacter pylori strains: a key factor of treatment failure. Gut 1995;37:A217.
13. Sanchez ML, Jones RN. E test, an antimicrobial susceptibility testing method with broad clinical and epidemiologic applications. Antimicrobic Newsletter 1993;8:1-8.
14. Glupczynski Y. Culture of Helicobacter pylori from gastric biopsies and antimicrobial susceptibility testing. In: Lee A, Mégraud F, eds. Helicobacter pylori: Techniques for Clinical Diagnosis & Basic Research. London: WB Saunders, 1996:17-32.
15. Cederbrant G, Kahlmeter G, Ljungh A. The E test for antimicrobial susceptibility testing of Helicobocter pylori. J Antimicrob Chemother 1993;31:65-71.
16. Glupcyznski Y, Labbe M, Hansen W, Crokaert F, Yourassowsky E. Evaluation of the E test for quantitative antimicrobial susceptibility testing of Helicobacter pylori. J Clin Microbiol 1991;29:2072-5.
17. Hirschl AM, Hirschl MM, Rotter ML. Comparison of three methods for the determination of the sensitivity of Helicobacter pylori to metronidazole. J Antimicrob Chemother 1993;32:45-9.
18. Neu HC. The development of macrolides: clarithromycin in perspective. J Antimicrob Chemother 1991;27(Suppl A):1-9.
19. Gustavson LE, Kaizer JF, Mukherjee DX, DeBartolo M, Schneck DW. Evaluation of pharmokinetic drug interactions between clarithromycin (c) and omeprazole (o). Am J Gastroenterol 1994;89:A1373.
20. Versalovic J, Kibler K, Small S, Graham DY, Go MF. Mutations in 23S ribosomal RNA confer clarithromycin resistance in Helicobacter pylori. Gut 1995;37:A266.